Skip to main content

Table 3 Comparison of the survival rate for the different imaging indices and time points after the initial TACE

From: Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?

Outcome variable OS > 6 months (n = 73) OS ≤ 6 months (n = 30) P-value
Lesion-to-liver contrast ratio 68 (38–100) 81 (26–120) 0.78
Venous percentage attenuation ratio 110 (101–124) 108 (100–122) 0.47
Delayed percentage attenuation ratio 122 (112–131) 115 (106–121) 0.04
Delayed percentage attenuation ratio ≥ 120 38 (52.1%) 8 (26.7%) 0.03
Outcome variable OS >  12 months (n = 40) OS ≤ 12 months (n = 63) P-value
Lesion-to-liver contrast ratio 67 (42–87) 69 (36–102) 0.64
Venous percentage attenuation ratio 109 (100–125) 109 (101–123) 0.89
Delayed percentage attenuation ratio 122 (111–131) 117 (110–126) 0.27
Delayed percentage attenuation ratio ≥ 120 22 (55.0%) 24 (38.1%) 0.11
Outcome variable OS >  18 months (n = 24) OS ≤ 18 months (n = 79) P-value
Lesion-to-liver contrast ratio 70 (54–105) 69 (36–100) 0.59
Venous percentage attenuation ratio 106 (98–118) 110 (102–123) 0.26
Delayed percentage attenuation ratio 122 (113–131) 118 (110–126) 0.31
Delayed percentage attenuation ratio ≥ 120 14 (58.3%) 32 (40.5%) 0.16
Outcome variable OS > 24 months (n = 12) OS ≤ 24 months (n = 91) P-value
Lesion-to-liver contrast ratio 72 (60–102) 69 (36–100) 0.38
Venous percentage attenuation ratio 100 (97–111) 110 (102–124) 0.05
Delayed percentage attenuation ratio 118 (111–131) 118 (110–128) 0.94
Delayed percentage attenuation ratio ≥ 120 6 (50.0%) 40 (44.0%) 0.76
  1. OS, overall survival.